68Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis

Introduction: Prostate cancer (PC) is the second most commonly diagnosed in males. 68Ga-PSMA PET/CT, a non-invasive diagnostic tool to evaluate PC with prostate-specific membrane antigen (PSMA) expression, has emerged as more accurate alternative assess disease staging. We aimed identify predictors of positive PET and accuracy this technique. Materials methods: Diagnostic cross-sectional study prospective retrospective approaches. performed comprehensive literature search on PubMed, Cochrane Library, Embase database studies including patients submitted radical prostatectomy or radiotherapy curative intent presented biochemical recurrence following ASTRO 1996 criteria. A total 35 involving 3910 68-Ga-PSMA were included independently assessed by two authors: 8 diagnosis, four staging, 23 restaging purposes. The significance level was α=0.05. Results: pooled sensitivity specificity 0.90 (0.86-0.93) (0.82-0.96), respectively, for purposes; 0.93 (0.86-0.98) 0.96 (0.92-0.99), respectively. In scenario, 0.76 (0.74-0.78) 0.45 (0.27-0.58), considering identification prostate each described situation. also obtained results PSA subdivisions. Conclusion: provides higher than traditional imaging cancer.